Hosted in association with
6:00 pm: RECEPTION 7:00 pm: EVENING PROGRAM BEGINS
Formal attire, black-tie optional
ACCOMMODATION: Hilton Québec (Click to book online)
Introducing our 2017 Inductees...
Michel G. Bergeron, a leading figure in the struggle against infectious disease and superbugs resistant to antimicrobials, is the founder of the Centre de recherche en infectiologie (CRI) of Laval University, now one of the largest infectious disease research centres in North America. In 1985, Dr. Bergeron began his search for rapid molecular (DNA-based) methods of accelerating the diagnosis of infectious diseases, which have reduced the time of diagnosis from more than 48 hours to less than one hour and enabled physicians to identify microbes and their antibiotic resistance genes and treat infectious diseases rapidly. Working with an interdisciplinary team, Professor Bergeron has developed technologies for detecting and identifying dangerous bacteria in health facilities, helping to contain or prevent dissemination of diseases and antibiotic resistance. The holder of 30 issued patents, he and his team are presently developing portable point-of-care diagnostic devices that can be used to bring easy-to-use health monitoring to people worldwide. His contributions include a protective vaginal gel or “Invisible Condom®” against the AIDS virus and other STDs and preventing neonatal meningitis, the development of unique safe water molecular analytical technologies, and service on national and international boards and committees.
Michel Chrétien has built a unified career around his own pro-hormone theory, bridging basic and clinical sciences to secure immediate medical benefits. Trained in endocrinology and protein chemistry, Dr. Chrétien graduated in Medicine in 1960. He published the pro-hormone theory in 1967, discovered human β-endorphin in 1976, and in 1990, proprotein convertases (PCs/PCSK1-PCSK9), which are implicated in many diseases including diabetes, obesity, cancer, atherosclerosis, dyslipidemia, and Alzheimer, as well as various viral and bacterial infections. Dr. Chrétien also discovered a beneficial PCSK9 mutation in French Canadian families which protect them from cardiovascular diseases. His work exemplifies ¨from bedside to bench and back”. Dr. Chrétien has authored 602 publications, and in the 1980’s, he was the seventh most cited scientist worldwide. Scientific director of two institutes (IRCM/Montréal) (Loeb/Ottawa), he has significantly boosted their growth and productivity. A fierce defender of scientific freedom, he has worked tirelessly to convince governments to invest in research and his skillful, diplomatic, and persistent promotion of science has helped transform Canada's research landscape for decades to come.
In a career spanning a half-century, Richard B. Goldbloom has served as Professor and Head of the Department of Pediatrics at Dalhousie University, Physician-in-Chief and Director of Research at the Izaak Walton Killam Hospital for Children in Halifax, and Chancellor of Dalhousie University. Scholar, scientist, and administrator, much honoured in Canada and worldwide, Dr. Goldbloom has devoted his life to improving the lives of children. He is admired for his unique ability to communicate with patients and their families and achieved international recognition as a pioneer of family participation in the care of hospitalized children, having introduced one of the first Care-by-Parent Units in Canada. He has authored hundreds of articles and seven books, including Pediatric Clinical Skills, a popular textbook for medical undergraduate and postgraduate students. Dr. Goldbloom has received many accolades including four honorary degrees and the F.N.G. Starr Award. In 2003, Dr. Goldbloom received a Canada Post National Literacy Award for his work promoting child literacy and in 2006, the Dr. Richard B. Goldbloom Research and Clinical Care Pavilion at the IWK Health Centre was named in his honour.
Born to a poor Irish family near Montreal in 1898, Emmett Hall studied law in Saskatchewan and served as Chief Justice of the province (appeal division) before his appointment to the Supreme Court in 1962. In 1961, at the request of the Diefenbaker government, Justice Hall led the Royal Commission on Health Services, interviewing hundreds of witnesses in public hearings, bringing attention to the challenges faced by ordinary men and women living with illness or injury. Asked in 1965 by Lester Pearson whether Tommy Douglas’ Saskatchewan experiment of government-funded health insurance could work nationwide, Justice Hall responded, “most definitely”. Justice Hall lived to age 95 and was active and influential in many major issues including Indigenous rights and the rights of the disabled. He has been described as “an establishment radical,” a man who understood power and the intricacies of politics, but who repeatedly sided with the common man and the needs of the poor. Challenged by opponents who believed expanded health care was too expensive, Justice Hall responded, “The only thing more expensive than good health care is no health care.”
Having profoundly advanced our understanding of the genetic basis of Huntington Disease (HD) and the pathways involved, one of the greatest hopes for an eventual treatment is the work of Killam Professor of Medical Genetics at the University of British Columbia and Canada Research Chair in Human Genetics and Molecular Medicine, Michael R. Hayden. Dr. Hayden is the most cited author in the world for HD and has written more than 840 peer-reviewed publications and invited submissions. His research into the mechanisms of HD have produced reliable predictive tests and new opportunities for prevention and treatment. Dr. Hayden’s work in deciphering vast and complex genomic and cellular data is advancing the work of identifying and unveiling secrets of intractable disease and his genetic research has generated new approaches to the costly and dangerous problem of adverse drug reactions (ADR). The Canadian Pharmacogenomics Network for Drug Safety (CPNDS), co-founded by Dr. Hayden, focuses on the development of genetic biomarkers for drug safety. Dr. Hayden currently serves as President of Global R&D and Chief Scientific Officer for TEVA Pharmaceuticals headquartered in Israel.
F. Estelle R. Simons, a physician-scientist, is internationally renowned for research on pharmacologic management of allergic diseases, including anaphylaxis and asthma. Her dedication to scholarship, innovative research and education helped transform allergic disease management from empiricism to science, relieve suffering, and mitigate the impact of the global allergy epidemic. Dr. Simons led an interdisciplinary team that conducted landmark investigations to establish the scientific basis for use of new medications that have since become safe and effective treatment for allergic diseases worldwide. With colleagues in immunology, she investigated new approaches to immune modulation. The editor or co-editor of eight textbooks, many of her 570 peer-reviewed publications are highly cited. Over four decades, Dr. Simons played an important role in building the specialty of Allergy & Clinical Immunology nationally and internationally through leadership in her field, serving as president of the Canadian Society of Allergy and Clinical Immunology and President of the American Academy of Allergy Asthma and Immunology. During a 15-year commitment to the World Allergy Organization, she chaired global initiatives on anaphylaxis, and brought the World Allergy Congress to Vancouver.